Compare Agilent Technologies Inc (A) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Lemonade Inc — how do they compare? Agilent Technologies Inc trades at $148.34 (market cap $42.22B), while Lemonade Inc trades at $51.48 (market cap $4.09B). The key difference: Agilent Technologies Inc is far larger — about 10.3× Lemonade Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| A | LMND | |
|---|---|---|
Market Cap | $42.22B | $4.09B |
Sector | Health | Financials |
52-Week High | $157.20 | $96.57 |
52-Week Low | $110.24 | $47.38 |
Enterprise Value | $43.77B | $3.95B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.77, up 0.03% on the day, near its consensus price target of $154.90. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 19.55% net income margin. Key developments include FDA and EU regulatory approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its biopharma portfolio.
Outlook remains positive with analyst consensus at Buy (77.5%) and a projected 4.1% upside to the price target. Risks include elevated valuation multiples (P/E 30.02) and dependence on healthcare sector growth. Earnings on August 26, 2026, will be critical for validating continued momentum amid competitive and macroeconomic pressures.
Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.
The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
